Matches in SemOpenAlex for { <https://semopenalex.org/work/W2918322716> ?p ?o ?g. }
- W2918322716 endingPage "1972" @default.
- W2918322716 startingPage "1963" @default.
- W2918322716 abstract "Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5-year survival has been achieved through cytoreductive surgery, combination platinum-based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long-term survival in late-stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug-resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on Critical Questions in Ovarian Cancer Research and Treatment was held in Pittsburgh, Pennsylvania, on October 1-3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease." @default.
- W2918322716 created "2019-03-11" @default.
- W2918322716 creator A5005621340 @default.
- W2918322716 creator A5007257045 @default.
- W2918322716 creator A5008988636 @default.
- W2918322716 creator A5009234043 @default.
- W2918322716 creator A5009400324 @default.
- W2918322716 creator A5013922346 @default.
- W2918322716 creator A5014887786 @default.
- W2918322716 creator A5016818540 @default.
- W2918322716 creator A5018749390 @default.
- W2918322716 creator A5019407817 @default.
- W2918322716 creator A5020081483 @default.
- W2918322716 creator A5022361893 @default.
- W2918322716 creator A5026961383 @default.
- W2918322716 creator A5027620152 @default.
- W2918322716 creator A5028580605 @default.
- W2918322716 creator A5029211907 @default.
- W2918322716 creator A5031553531 @default.
- W2918322716 creator A5034156211 @default.
- W2918322716 creator A5036444245 @default.
- W2918322716 creator A5037541103 @default.
- W2918322716 creator A5040450413 @default.
- W2918322716 creator A5040791524 @default.
- W2918322716 creator A5041227791 @default.
- W2918322716 creator A5043845770 @default.
- W2918322716 creator A5048102923 @default.
- W2918322716 creator A5051525398 @default.
- W2918322716 creator A5056805446 @default.
- W2918322716 creator A5058249824 @default.
- W2918322716 creator A5058837420 @default.
- W2918322716 creator A5059909958 @default.
- W2918322716 creator A5061389369 @default.
- W2918322716 creator A5063379605 @default.
- W2918322716 creator A5065593057 @default.
- W2918322716 creator A5070555068 @default.
- W2918322716 creator A5073323475 @default.
- W2918322716 creator A5076251961 @default.
- W2918322716 creator A5076392308 @default.
- W2918322716 creator A5076541737 @default.
- W2918322716 creator A5084233435 @default.
- W2918322716 creator A5085086748 @default.
- W2918322716 creator A5088086867 @default.
- W2918322716 creator A5089425681 @default.
- W2918322716 creator A5090218407 @default.
- W2918322716 date "2019-03-05" @default.
- W2918322716 modified "2023-10-14" @default.
- W2918322716 title "Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference" @default.
- W2918322716 cites W1488106034 @default.
- W2918322716 cites W1512321076 @default.
- W2918322716 cites W1714818982 @default.
- W2918322716 cites W1863225814 @default.
- W2918322716 cites W1970578083 @default.
- W2918322716 cites W1984373702 @default.
- W2918322716 cites W1993043513 @default.
- W2918322716 cites W1997338647 @default.
- W2918322716 cites W1997958279 @default.
- W2918322716 cites W2040022677 @default.
- W2918322716 cites W2077145482 @default.
- W2918322716 cites W2091107854 @default.
- W2918322716 cites W2103386635 @default.
- W2918322716 cites W2111437716 @default.
- W2918322716 cites W2134919151 @default.
- W2918322716 cites W2139290963 @default.
- W2918322716 cites W2151509048 @default.
- W2918322716 cites W2160466424 @default.
- W2918322716 cites W2214802907 @default.
- W2918322716 cites W2314851760 @default.
- W2918322716 cites W2320129379 @default.
- W2918322716 cites W2476568892 @default.
- W2918322716 cites W2501351815 @default.
- W2918322716 cites W2508673657 @default.
- W2918322716 cites W2513362995 @default.
- W2918322716 cites W2515679040 @default.
- W2918322716 cites W2526078391 @default.
- W2918322716 cites W2528228811 @default.
- W2918322716 cites W2531389956 @default.
- W2918322716 cites W2557666746 @default.
- W2918322716 cites W2561432266 @default.
- W2918322716 cites W2561471811 @default.
- W2918322716 cites W2581283756 @default.
- W2918322716 cites W2590528754 @default.
- W2918322716 cites W2594301310 @default.
- W2918322716 cites W2603744382 @default.
- W2918322716 cites W2620099337 @default.
- W2918322716 cites W2622683216 @default.
- W2918322716 cites W2633266064 @default.
- W2918322716 cites W2733154631 @default.
- W2918322716 cites W2737389832 @default.
- W2918322716 cites W2745902885 @default.
- W2918322716 cites W2747510162 @default.
- W2918322716 cites W2747939174 @default.
- W2918322716 cites W2750694869 @default.
- W2918322716 cites W2765410042 @default.
- W2918322716 cites W2767122952 @default.
- W2918322716 cites W2769136370 @default.
- W2918322716 cites W2771506486 @default.
- W2918322716 cites W2773771998 @default.